CSIMarket
 


Anavex Life Sciences Corp   (AVXL)
Other Ticker:  
 
 

AVXL's Revenue Growth by Quarter and Year

Anavex Life Sciences 's Revenue results by quarter and year




AVXL Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter September - 0.67 2.20 3.86
III Quarter June - 0.56 0.18 -0.13
II Quarter March - 0.75 1.11 0.33
I Quarter December 0.59 0.76 0.87 0.16
FY   0.59 2.74 4.36 4.22



AVXL Revenue first quarter 2024 Y/Y Growth Comment
Anavex Life Sciences Corp reported decline in Revenue in the first quarter 2024 by -22.11% to $ 0.59 millions, from the same quarter in 2023.
The contraction in the first quarter 2024 Anavex Life Sciences Corp 's Revenue compares unfavorably to the Company's average Revenue doubling of 213.47%.

Looking into first quarter 2024 results within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue growth. While Anavex Life Sciences Corp ' s Revenue fall of -22.11% ranks overall at the positon no. 1843 in the first quarter 2024.




AVXL Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter September - -69.55 % -43.01 % 1186.67 %
III Quarter June - 211.11 % - -
II Quarter March - -32.43 % 236.36 % 94.12 %
I Quarter December -22.11 % -12.64 % 443.75 % 100 %
FY   - -37.16 % 3.32 % 1040.54 %

Financial Statements
Anavex Life Sciences 's first quarter 2024 Revenue $ 0.59 millions AVXL's Income Statement
Anavex Life Sciences 's first quarter 2023 Revenue $ 0.76 millions Quarterly AVXL's Income Statement
New: More AVXL's historic Revenue Growth >>


AVXL Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter September - 19.64 % 1122.22 % -
III Quarter June - -25.33 % -83.78 % -
II Quarter March - -1.32 % 27.59 % 106.25 %
I Quarter December -11.64 % -65.45 % -77.46 % -46.67 %
FY (Year on Year)   - -37.16 % 3.32 % 1040.54 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #224
Overall #1843

Revenue Y/Y Growth Statistics
High Average Low
2362.56 % 213.47 % -91.31 %
(Sep 30 2021)   (Dec 31 2016)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #224
Overall #1843
Revenue Y/Y Growth Statistics
High Average Low
2362.56 % 213.47 % -91.31 %
(Sep 30 2021)   (Dec 31 2016)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Anavex Life Sciences 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1551.59 % 99.21 % -95.59 %
(Jun 30 2018)  


AVXL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Anavex Life Sciences Corp reported drop in Revenue from the previous quarter by -11.64% to $ 0.59 millions, from $ 0.67 millions released in the previous reporting period.

If you look into present shortcoming in the quarter, you should presume, that commonly I. Quarter performance occur weaker in contrast to the quarter before, Alexandra Parker, Biotechnology & Pharmaceuticals industry consultant from Seattle added.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Anavex Life Sciences 's Revenue growth quarter on quarter, overall rank is 309.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #20
Overall #309
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #20
Overall #309
Revenue Q/Q Growth Statistics
High Average Low
1551.59 % 99.21 % -95.59 %
(Jun 30 2018)  


AVXL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Anavex Life Sciences Corp reported drop in Revenue from the previous quarter by -11.64% to $ 0.59 millions, from $ 0.67 millions declared in the previous reporting period.

This is not important problem, as Revenue always tend to slow in the I. Quarter.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Anavex Life Sciences 's Revenue growth quarter on quarter, overall rank is 309.


Anavex Life Sciences 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 2.58 $ 2.74 $ 4.27 $ 3.89 $ 4.25
Y / Y Revenue Growth (TTM) -39.35 % -37.09 % -29.07 % -31.91 % -13.78 %
Year on Year Revenue Growth Overall Ranking # 685 # 1692 # 12 # 16 # 14
Seqeuential Revenue Change (TTM) -6.07 % -35.77 % 9.91 % -8.52 % -2.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 1460 # 2886 # 1453 # 778 # 869




Cumulative Revenue growth Comment
Anavex Life Sciences 's cumulative 12 months Revenue continue to drop, but on the faster rate at -39.35% year on year, at Dec 31 2023 compare to the -37.09% decrease at Sep 30 2023. If the Anavex Life Sciences 's fiscal year would end at Dec 31 2023, annual Revenue would be $3 millions.

In the Healthcare sector 74 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 685, from total ranking in previous quarter at 1692.

Revenue TTM Q/Q Growth Statistics
High Average Low
1013.45 %
166.05 %
-79.58 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 17
Healthcare Sector # 75
Overall # 685

Revenue TTM Y/Y Growth Statistics
High Average Low
1013.45 %
166.05 %
-79.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 206
S&P 500 # 1460
Cumulative Revenue growth Comment
Anavex Life Sciences 's cumulative 12 months Revenue continue to drop, but on the faster rate at -39.35% year on year, at Dec 31 2023 compare to the -37.09% decrease at Sep 30 2023. If the Anavex Life Sciences 's fiscal year would end at Dec 31 2023, annual Revenue would be $3 millions.

In the Healthcare sector 74 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 685, from total ranking in previous quarter at 1692.

Revenue TTM Q/Q Growth Statistics
High Average Low
1013.45 %
166.05 %
-79.58 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 17
Healthcare Sector # 75
Overall # 685

Revenue TTM Y/Y Growth Statistics
High Average Low
1013.45 %
166.05 %
-79.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 206
S&P 500 # 1460




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AVXL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for AVXL's Competitors
Revenue Growth for Anavex Life Sciences 's Suppliers
Revenue Growth for AVXL's Customers

You may also want to know
AVXL's Annual Growth Rates AVXL's Profitability Ratios AVXL's Asset Turnover Ratio AVXL's Dividend Growth
AVXL's Roe AVXL's Valuation Ratios AVXL's Financial Strength Ratios AVXL's Dividend Payout Ratio
AVXL's Roa AVXL's Inventory Turnover Ratio AVXL's Growth Rates AVXL's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions
Eton Pharmaceuticals Inc -9.72%$ -9.720 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com